<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051596</url>
  </required_header>
  <id_info>
    <org_study_id>2009-170</org_study_id>
    <nct_id>NCT01051596</nct_id>
  </id_info>
  <brief_title>A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer</brief_title>
  <official_title>A Phase II Study of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP) in Combination With Temozolomide in Patients With Heavily Pretreated, Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with colorectal cancer that cannot be cured by surgery are being asked to participate
      in this study.

      The purpose of this study is to test the efficacy (effectiveness) of a new combination of
      drugs, ABT-888 and temozolomide for patients with colorectal cancer. Temozolomide acts by
      damaging deoxyribonucleic acid (DNA) in rapidly dividing cells, in other words, cancer cells.
      ABT-888 inhibits an enzyme called &quot;PARP&quot; which helps to fix damaged DNA. By inhibiting this
      enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the temozolomide,
      and will hopefully increase the killing of cancer cells, and decrease the tumors in the body.

      ABT-888 is an investigational or experimental anti-cancer agent that has not yet been
      approved by the Food and Drug Administration (FDA) for use in colorectal cancer.

      This study will help find out what effects (good and bad) the combination of drugs,
      temozolomide and ABT-888 has on colorectal cancer.

      This research is being done because it is not known if ABT-888 will increase the
      effectiveness of temozolomide for colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will initiate a single arm, open label Phase II study to test the clinical activity of
      ABT-888 and temozolomide in patients with metastatic colorectal cancer.

      Treatment will continue weekly with restaging scans to be performed every 8 weeks. The trial
      will follow a Simon's two-stage optimal design. For the first stage, 21 patients will be
      accrued. If two (9.5%) or fewer of the 21 patients exhibit a partial or complete response
      with ABT-888 plus temozolomide, the agent will be rejected and the trial stopped. However, if
      at least 3 patients of the 21 (14%) exhibit a response in the first stage, then an additional
      29 patients will be entered into the second stage, for a total of 50 patients in this phase
      II study. If 8 (16%) or more patients exhibit a response, then the treatment will be
      considered for further investigation. The sample sizes of 21 and 50 patients and the decision
      rules, in stages 1 and 2 respectively, are designed to differentiate a 25% overall response
      rate from a 10% overall response rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients With Disease Control</measure>
    <time_frame>2 months</time_frame>
    <description>Disease control rate defined as stable disease, partial response, or complete response according to the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival Time</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival defines as the time in days from study study entry until progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival defined as the time in days from study entry until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With an Objective Response</measure>
    <time_frame>2 months</time_frame>
    <description>Objective response rate defined as partial response or complete response according to RECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ABT-888 and temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>150mg/m2 Days 1-5 of each 28 day cycle</description>
    <arm_group_label>ABT-888 and temozolomide</arm_group_label>
    <other_name>Temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-888</intervention_name>
    <description>40mg orally BID Days 1-7 of each 28 day cycle</description>
    <arm_group_label>ABT-888 and temozolomide</arm_group_label>
    <other_name>Veliparib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven colorectal cancer with measurable or evaluable disease

          -  Progression on or intolerance of or ineligibility for all standard therapies
             (including regimens containing fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab,
             and an anti-EGFR antibody (where appropriate))

          -  Age &gt; = 18 years

          -  ECOG performance status 0-2

          -  Subjects with no brain metastases or a history of previously treated brain metastases
             who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior
             to enrollment and have a baseline MRI that shows no evidence of active intercranial
             disease and have not had treatment with steroids within 1 week of study enrollment

          -  At least 21 days since prior anti-cancer therapy, including chemotherapy, biological
             therapy, radiation therapy or any investigational agent within 4 weeks before starting
             ABT-888 and temozolomide

          -  Adequate hepatic, bone marrow, and renal function

          -  Partial thromboplastin time (PTT) must be &lt;/= 1.5 x the upper limit of institution's
             normal range and INR &lt; 1.5. Subjects on anticoagulant will have PTT and INR as
             determined by the investigator.

          -  Subject's with significant fluid retention, including ascites or pleural effusion, may
             be allowed at the discretion of the PI

          -  Life expectancy &gt; 12 weeks

          -  Women of childbearing potential must have a negative serum pregnancy test within 14
             days prior to initiation of treatment and/or postmenopausal women must be amenorrheic
             for at least 12 months to be considered of non-childbearing potential.

          -  Subject is capable of understanding and complying with parameters as outlined in the
             protocol and able to sign and date the informed consent approved by the IRB prior to
             the initiation of any screening or study-specific procedures.

        Exclusion Criteria:

          -  CNS metastases which do not meet the criteria outlined in inclusion criteria

          -  Active severe infection or known chronic infection with HIV, hepatitis B virus, or
             hepatitis C virus

          -  Cardiovascular disease problems including unstable angina, therapy for
             life-threatening ventricular arrhythmia, myocardial infarction, stroke or congestive
             heart failure within the last 6 months

          -  Life threatening visceral disease or other severe concurrent disease

          -  Women who are pregnant or breastfeeding

          -  Anticipated patient survival under 3 months

          -  The subject has had another active malignancy within the past five years except for
             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of
             the skin.

          -  Clinically significant and uncontrolled major medical conditions including but not
             limited to: active uncontrolled infection, symptomatic congestive heart failure,
             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation
             that would limit compliance with study requirements; any medical condition, which in
             the opinion of the study investigator places the subject at an unacceptably high risk
             for toxicities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Pishvaian, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <results_first_submitted>March 10, 2019</results_first_submitted>
  <results_first_submitted_qc>March 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2019</results_first_posted>
  <last_update_submitted>March 10, 2019</last_update_submitted>
  <last_update_submitted_qc>March 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Michael J Pishvaian</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ABT-888 and Temozolomide</title>
          <description>Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
Temozolomide: 150mg/m2 Days 1-5 of each 28 day cycle
ABT-888: 40mg orally BID Days 1-7 of each 28 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABT-888 and Temozolomide</title>
          <description>Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
Temozolomide: 150mg/m2 Days 1-5 of each 28 day cycle
ABT-888: 40mg orally BID Days 1-7 of each 28 day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="35" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients With Disease Control</title>
        <description>Disease control rate defined as stable disease, partial response, or complete response according to the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
        <time_frame>2 months</time_frame>
        <population>Percent of patients with disease control, according to the Response Evaluation Criteria in Solid Tumors (RECIST).</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-888 and Temozolomide</title>
            <description>Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
Temozolomide: 150mg/m2 Days 1-5 of each 28 day cycle
ABT-888: 40mg orally BID Days 1-7 of each 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Disease Control</title>
          <description>Disease control rate defined as stable disease, partial response, or complete response according to the Response Evaluation Criteria in Solid Tumors (RECIST).</description>
          <population>Percent of patients with disease control, according to the Response Evaluation Criteria in Solid Tumors (RECIST).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival Time</title>
        <description>Progression-free survival defines as the time in days from study study entry until progression or death</description>
        <time_frame>1 year</time_frame>
        <population>All patients were evaluable for response, on an intention to treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-888 and Temozolomide</title>
            <description>Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
Temozolomide: 150mg/m2 Days 1-5 of each 28 day cycle
ABT-888: 40mg orally BID Days 1-7 of each 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival Time</title>
          <description>Progression-free survival defines as the time in days from study study entry until progression or death</description>
          <population>All patients were evaluable for response, on an intention to treat basis</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.6" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival defined as the time in days from study entry until death</description>
        <time_frame>1 year</time_frame>
        <population>All patients were evaluable for response, on an intention to treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-888 and Temozolomide</title>
            <description>Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
Temozolomide: 150mg/m2 Days 1-5 of each 28 day cycle
ABT-888: 40mg orally BID Days 1-7 of each 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival defined as the time in days from study entry until death</description>
          <population>All patients were evaluable for response, on an intention to treat basis</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="5.6" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With an Objective Response</title>
        <description>Objective response rate defined as partial response or complete response according to RECIST criteria</description>
        <time_frame>2 months</time_frame>
        <population>All patients were evaluable for response, on an intention to treat basis</population>
        <group_list>
          <group group_id="O1">
            <title>ABT-888 and Temozolomide</title>
            <description>Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
Temozolomide: 150mg/m2 Days 1-5 of each 28 day cycle
ABT-888: 40mg orally BID Days 1-7 of each 28 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With an Objective Response</title>
          <description>Objective response rate defined as partial response or complete response according to RECIST criteria</description>
          <population>All patients were evaluable for response, on an intention to treat basis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ABT-888 and Temozolomide</title>
          <description>Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
Temozolomide: 150mg/m2 Days 1-5 of each 28 day cycle
ABT-888: 40mg orally BID Days 1-7 of each 28 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fevers and low neutrophil count</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Low platelets</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Low Platelets</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Low red blood cells</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <description>Low white blood cells</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Low neutrophils</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>Low lymphocytes</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urinary Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Petechiae/Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Peeling of feet</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Pishvaian, MD, PhD</name_or_title>
      <organization>Georgetown University</organization>
      <phone>202-444-2223</phone>
      <email>pishvaim@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

